Atogepant (Qulipta) for Migraine Prevention

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2021年 / 63卷 / 1636期
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：169 / 171
页数：3
相关论文
共 50 条
  • [41] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [42] Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine
    Ailani, Jessica
    Lipton, Richard
    Goadsby, Peter
    Guo, Hua
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2021, 96 (15)
  • [43] Daily atogepant provides a rapid onset and sustained benefit in the preventive treatment of migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 119 - 119
  • [44] Atogepant significantly reduces mean monthly migraine days in the phase 3 trial (ADVANCE) for the preventive treatment of migraine
    Ailani, J.
    Lipton, R. B.
    Goadsby, P. J.
    Guo, H.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 99 - 100
  • [45] Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
    Goadsby, P.
    Pozo-Rosich, P.
    Ashina, M.
    Reuter, U.
    Moisset, X.
    Trugman, J.
    Ha, H.
    Schwefel, B.
    Nagy, K.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [46] High-responder rates of atogepant in refractory chronic migraine: A retrospective analysis
    Baek, William
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [47] Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Gandhi, P.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 212 - 213
  • [48] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [49] Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 159
  • [50] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 160
12345